Physician profile
Baba H Limann
NPI 1518990001
$2,452.17
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $107 · 2021: $365 · 2022: $268 · 2023: $131 · 2024: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $423.82 | 2019-2024 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $363.15 | 2020-2022 | |
| Glaxosmithkline, LLC. | $304.12 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $267.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.38 | 2019-2024 | |
| United Therapeutics Corporation | $165.03 | 2019-2023 | |
| Insmed, INC. | $149.53 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $117.72 | 2024 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $103.18 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $90.15 | 2024 | Dupixent |
| Grifols USA, LLC | $46.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.95 | 2019 | |
| Mylan Specialty L.P. | $24.47 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.95 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.31 | 2019 | |
| Circassia INC. | $15.66 | 2020 | |
| Shire North American Group INC | $15.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.95 | 2019 | |
| Genentech USA, INC. | $13.10 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baba Limann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.